Nissay Asset Management’s 10x Genomics TXG Stock Holding History

Nissay Asset Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,426	Closed	-$641K	–	772
2022 Q1	$641K	Buy	8,426 +284	+3%	+$24.8K	0.01%	679
2021 Q4	$1.21M	Buy	8,142 +84	+1%	+$12.9K	0.01%	607
2021 Q3	$1.17M	Buy	8,058 +365	+5%	+$62.7K	0.01%	590
2021 Q2	$1.51M	Buy	7,693 +648	+9%	+$117K	0.01%	528
2021 Q1	$1.27M	Buy	7,045 +75	+1%	+$13K	0.01%	552
2020 Q4	$987K	Buy	+6,970	New	+$1.01M	0.01%	589

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Nissay Asset Management's TXG Position: Q2 2022 in Review

Nissay Asset Management sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 8,426 shares — an estimated $641K sold.

Nissay Asset Management first reported a position in TXG in Q4 2020 and held it in 6 quarters. The position peaked at $1.51M in Q2 2021. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

Nissay Asset Management reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
Nissay Asset Management sold 8,426 10x Genomics shares in Q2 2022, an estimated $641K.
Nissay Asset Management first reported a position in 10x Genomics in Q4 2020 and held it in 6 quarters.
Nissay Asset Management's 10x Genomics position peaked at $1.51M in Q2 2021.
254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Nissay Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.